Prelude Therapeutics Inc has 6 Schedule 13D or 13G filings on record since 2025-11-07. 6 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Orbimed Advisors LLC | 16% | 12,935,071 | SCHEDULE 13D/A, 2026-04-23 | 2026-04-21 |
| Baker Bros. Advisors LP | 15.5% | 10,295,301 | SCHEDULE 13D/A, 2026-04-22 | 2026-04-20 |
| Vaddi Krishna | 13.15% | 6,745,647 | SCHEDULE 13G/A, 2026-02-13 | 2025-12-31 |
| Incyte Corp | 9.9% | 4,372,124 | SCHEDULE 13G, 2025-11-07 | 2025-11-03 |
| RA Capital Management, L.P. | 9.9% | 6,477,309 | SCHEDULE 13G, 2026-04-28 | 2026-04-21 |
| Soleus Capital Management, L.P. | 5.2% | 3,378,378 | SCHEDULE 13G, 2026-07-08 | 2026-04-21 |
Purpose of Transaction (Item 4)
Baker Bros. Advisors LP
Item 4 of Schedule 13D is supplemented and amended, as the case may be, as follows: The disclosure in Item 6 below is incorporated herein by reference. On April 20, 2026, Prelude Therapeutics Incorporated (the "Issuer") entered into an underwriting agreement (the "Underwriting Agreement") with Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Citizens JMP Securities LLC (the "Underwriters"), related to a public offering (the "Offering") of 18,018,014 shares of common stock of the Issuer ("Common Stock"), at a price to the public of $4.44 per share and in lieu of Common Stock to investors who so chose, prefunded warrants to purchase up to 2,252,252 shares of the Issuer's Common Stock (the "Prefunded Warrants"), at a price to the public of $4.4399 per warrant with an exercise price of $0.0001 per share. The Offering closed on April 21, 2026. Pursuant to the Offering, 667 and Life Sciences purchased 114,601 and 2,137,651 Prefunded Warrants, respectively, at the offering price of $4.4399 per share, totaling 2,252,252 Prefunded Warrants in the aggregate. Each of 667 and Life Sciences purchased the Prefunded Warrants with their working capital. The Funds hold securities of the Issuer for investment purposes. The Reporting Persons or their affiliates may purchase additional securities or dispose of securities in varying amounts and at varying times depending upon the Reporting Persons' continuing assessments of pertinent factors, including the availability of shares of Common …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-04-22; the filing has the rest
Orbimed Advisors LLC
The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of Shares or otherwise, they may acquire Shares or other securities of the Issuer either in the open market or in privately negotiated transactions. Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Shares currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions. Except as set forth in this Schedule 13D, the Reporting Persons have not formulated any plans or proposals which relate to or would result in: (a) the acquisition by any person of additional securities of the Issuer or the disposition of securities of the Issuer, (b) an extraordinary corporate transaction, such as a merger, reorganization or …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-04-23; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-11-07 | Incyte Corp | 9.9% | SCHEDULE 13G |
| 2026-02-13 | Vaddi Krishna | 13.15% | SCHEDULE 13G/A |
| 2026-04-22 | Baker Bros. Advisors LP | 15.5% | SCHEDULE 13D/A |
| 2026-04-23 | Orbimed Advisors LLC | 16% | SCHEDULE 13D/A |
| 2026-04-28 | RA Capital Management, L.P. | 9.9% | SCHEDULE 13G |
| 2026-07-08 | Soleus Capital Management, L.P. | 5.2% | SCHEDULE 13G |
Tools for this story
Each opens in a new tab, filled in for Prelude Therapeutics Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.